[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642372":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":47,"studyPopulation":47,"armGroups":53,"interventions":69,"overallOfficials":47,"centralContacts":85,"locations":94,"responsibleParty":276,"collaborators":47,"id":278,"slug":279,"hasResults":280,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":280,"sex":286,"minAge":287,"maxAge":47,"enrollmentInfo":288,"targetDuration":47,"studyType":291,"phases":292,"briefSummary":294,"conditions":295,"keywords":47,"overallStatus":97,"whyStopped":47,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":306},{"fullName":5,"class":6},"Verastem, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":18,"otherOutcomes":40},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only","Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR)","6 months",{"measure":14,"description":15,"timeFrame":12},"To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC","Proportion\u002Fnumber of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions\u002Freductions and discontinuations",{"measure":17,"description":15,"timeFrame":12},"To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC",[19,23,27,30,34,37],{"measure":20,"description":21,"timeFrame":22},"Confirmed ORR per RECIST v1.1 assessed by BICR (primary) and Investigator (secondary) assessments","To evaluate additional efficacy parameters of VS-7375 monotherapy and VS-7375 in combination with cetuximab or panitumumab or cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated CRC","24 months",{"measure":24,"description":25,"timeFrame":26},"Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, Cmax","Maximum concentration (Cmax)","20 weeks",{"measure":28,"description":29,"timeFrame":26},"Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, AUC","Area under plasma Concentration (AUC) 0 to t",{"measure":31,"description":32,"timeFrame":33},"To evaluate Pharmacodynamics (PD) and other relevant blood tumor markers specific to tumor type","CA19-9, CEA, CA-125","Up to 2.5 years",{"measure":35,"description":36,"timeFrame":22},"To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30)","The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of colorectal cancer patients",{"measure":38,"description":39,"timeFrame":22},"Time to next therapy","To assess the interval between initiation of study treatment and initiation of subsequent treatment",[41],{"measure":42,"description":43,"timeFrame":22},"Imaging of tumor metabolism changes in 2L monotherapy patients","To assess tumor metabolism dynamics on FDG-PET\u002FCT",{"allocation":45,"interventionModel":46,"interventionModelDescription":47,"primaryPurpose":48,"observationalModel":47,"timePerspective":47,"maskingInfo":49},"RANDOMIZED","CROSSOVER",null,"TREATMENT",{"masking":50,"maskingDescription":47,"whoMasked":51},"SINGLE",[52],"OUTCOMES_ASSESSOR",[54,62,65],{"label":55,"type":56,"description":57,"interventionNames":58},"VS-7375 Monotherapy or Preferred Combination in 2L+ CRC","EXPERIMENTAL","Participants randomized to a treatment in 2:1 ratio",[59,60,61],"Drug: VS-7375","Drug: cetuximab","Drug: panitumumab",{"label":63,"type":56,"description":47,"interventionNames":64},"VS-7375 with chosen regimen in 2L+ CRC",[59,60,61],{"label":66,"type":56,"description":47,"interventionNames":67},"VS-7375 + cetuximab and mFOLFOX in 1L CRC",[68],"Drug: Cetuximab + mFOLFOX6",[70,75,79,82],{"type":71,"name":72,"description":73,"armGroupLabels":74,"otherNames":47},"DRUG","VS-7375","Taken by mouth",[55,63],{"type":71,"name":76,"description":77,"armGroupLabels":78,"otherNames":47},"cetuximab","Intravenous infusion",[55,63],{"type":71,"name":80,"description":77,"armGroupLabels":81,"otherNames":47},"panitumumab",[55,63],{"type":71,"name":83,"description":77,"armGroupLabels":84,"otherNames":47},"Cetuximab + mFOLFOX6",[66],[86,91],{"name":87,"role":88,"phone":89,"phoneExt":47,"email":90},"Verastem Call Center","CONTACT","7812924204","VS-7375-203TrialSupport@verastem.com",{"name":92,"role":88,"phone":47,"phoneExt":47,"email":93},"Luke Chung, MD","VS-7375-203Medical@verastem.com",[95,117,130,147,164,179,194,209,224,241,259],{"facility":96,"status":97,"city":98,"state":99,"zip":100,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":108,"contacts":109},"START Los Angeles","RECRUITING","Los Angeles","California","90025","United States","US",{"type":104,"coordinates":105},"Point",[106,107],-118.24368,34.05223,{"lat":107,"lon":106},[110,114],{"name":111,"role":88,"phone":112,"phoneExt":47,"email":113},"START Hope Team","424-465-1820","hopeteam@startresearch.com",{"name":115,"role":116,"phone":47,"phoneExt":47,"email":47},"Navid Hafez, M.D., MPH","PRINCIPAL_INVESTIGATOR",{"facility":118,"status":97,"city":98,"state":99,"zip":119,"country":101,"countryCode":102,"cosmosGeoPoint":120,"geoPoint":122,"contacts":123},"Valkyrie Clinical Trials (contact for more locations)","90067",{"type":104,"coordinates":121},[106,107],{"lat":107,"lon":106},[124,128],{"name":125,"role":88,"phone":126,"phoneExt":47,"email":127},"Trenis Palmer, PhD","912-398-3205","trenis.palmer@vctcare.com",{"name":129,"role":116,"phone":47,"phoneExt":47,"email":47},"David Berz, MD, PhD, MPH",{"facility":131,"status":97,"city":132,"state":133,"zip":134,"country":101,"countryCode":102,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":104,"coordinates":136},[137,138],-82.45843,27.94752,{"lat":138,"lon":137},[141,145],{"name":142,"role":88,"phone":143,"phoneExt":47,"email":144},"Cheyenne Schneider","813-745-3691","Cheyenne.Schneider@moffitt.org",{"name":146,"role":116,"phone":47,"phoneExt":47,"email":47},"Tiago Biachi de Castria, MD, PhD",{"facility":148,"status":97,"city":149,"state":150,"zip":151,"country":101,"countryCode":102,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Indiana University, Simon Comprehensive Cancer Center","Indianapolis","Indiana","46202",{"type":104,"coordinates":153},[154,155],-86.15804,39.76838,{"lat":155,"lon":154},[158,162],{"name":159,"role":88,"phone":160,"phoneExt":47,"email":161},"Yvonne LaFary","317-278-5613","ylafary@iu.edu",{"name":163,"role":116,"phone":47,"phoneExt":47,"email":47},"Anita Turk, M.D.",{"facility":165,"status":97,"city":166,"state":167,"zip":168,"country":101,"countryCode":102,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"START Midwest","Grand Rapids","Michigan","49546",{"type":104,"coordinates":170},[171,172],-85.66809,42.96336,{"lat":172,"lon":171},[175,177],{"name":111,"role":88,"phone":176,"phoneExt":47,"email":113},"616-954-5554",{"name":178,"role":116,"phone":47,"phoneExt":47,"email":47},"Sreenivasa R Chandana, M.D., Ph.D.",{"facility":180,"status":97,"city":181,"state":182,"zip":183,"country":101,"countryCode":102,"cosmosGeoPoint":184,"geoPoint":188,"contacts":189},"START New Jersey","East Brunswick","New Jersey","08816",{"type":104,"coordinates":185},[186,187],-74.41598,40.42788,{"lat":187,"lon":186},[190,192],{"name":111,"role":88,"phone":191,"phoneExt":47,"email":113},"732-426-4750",{"name":193,"role":116,"phone":47,"phoneExt":47,"email":47},"Bruno S Fang, M.D.",{"facility":195,"status":97,"city":196,"state":197,"zip":198,"country":101,"countryCode":102,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"START Dallas Fort Worth","Fort Worth","Texas","76104",{"type":104,"coordinates":200},[201,202],-97.32085,32.72541,{"lat":202,"lon":201},[205,207],{"name":111,"role":88,"phone":206,"phoneExt":47,"email":113},"682-350-3010",{"name":208,"role":116,"phone":47,"phoneExt":47,"email":47},"Salwan Al Mutar, M.D., M.Sc.",{"facility":210,"status":97,"city":211,"state":212,"zip":213,"country":101,"countryCode":102,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"START Mountain Region","West Valley City","Utah","84119",{"type":104,"coordinates":215},[216,217],-112.00105,40.69161,{"lat":217,"lon":216},[220,222],{"name":111,"role":88,"phone":221,"phoneExt":47,"email":113},"801-907-4750",{"name":223,"role":116,"phone":47,"phoneExt":47,"email":47},"José M Pacheco, M.D.",{"facility":225,"status":97,"city":226,"state":227,"zip":228,"country":101,"countryCode":102,"cosmosGeoPoint":229,"geoPoint":233,"contacts":234},"UVA Comprehensive Cancer Center","Charlottesville","Virginia","22908",{"type":104,"coordinates":230},[231,232],-78.47668,38.02931,{"lat":232,"lon":231},[235,239],{"name":236,"role":88,"phone":237,"phoneExt":47,"email":238},"Clinical Trials Navigator","434-982-0539","UVACANCERTRIALS@uvahealth.org",{"name":240,"role":116,"phone":47,"phoneExt":47,"email":47},"Matthew Reilley, MD",{"facility":242,"status":97,"city":243,"state":244,"zip":245,"country":246,"countryCode":247,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"Icon Cancer Centre South Brisbane","South Brisbane","Queensland","4101","Australia","AU",{"type":104,"coordinates":249},[250,251],153.02049,-27.48034,{"lat":251,"lon":250},[254,257],{"name":242,"role":88,"phone":255,"phoneExt":47,"email":256},"07 3737 4700","admin.southbrisbane@icon.team",{"name":258,"role":116,"phone":47,"phoneExt":47,"email":47},"Jermaine Coward, MBBS, MRCP (UK), FRACP, PhD",{"facility":260,"status":97,"city":261,"state":262,"zip":263,"country":246,"countryCode":247,"cosmosGeoPoint":264,"geoPoint":268,"contacts":269},"Icon Cancer Centre Adelaide","Kurralta Park","South Australia","5037",{"type":104,"coordinates":265},[266,267],138.56702,-34.95142,{"lat":267,"lon":266},[270,274],{"name":271,"role":88,"phone":272,"phoneExt":47,"email":273},"Icon Cancer Centre Adelaide\u002FKurralta Park","08 8474 0220","admin.adelaide@icon.team",{"name":275,"role":116,"phone":47,"phoneExt":47,"email":47},"Carolyn Bampton, MBBS, FRACP",{"type":277,"investigatorFullName":47,"investigatorTitle":47,"investigatorAffiliation":47,"oldNameTitle":47,"oldOrganization":47},"SPONSOR","100642372","phase-2-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-colorectal-cancer-100642372",false,"NCT07659795","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)","TARGET-D 203","Inclusion Criteria:\n\n* Histopathology confirmed metastatic CRC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n\n  2L+ patients:\n* Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma\n* Have documented disease progression during or following their most recent prior line of therapy\n* Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy.\n\n  1L patients:\n* Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease.\n\nExclusion Criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose\n* Receipt of prior direct RAS inhibitor\n* Receipt of more than 1 investigational therapy\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":289,"type":290},150,"ESTIMATED","INTERVENTIONAL",[293],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer",[296],"Colorectal Cancer","2026-08-21",{"date":299,"type":300},"2026-08-24","ACTUAL",{"date":302,"type":300},"2026-07-28",{"date":304,"type":290},"2028-12",{"name":5,"class":6},11]